Literature DB >> 17363471

Endoproteolytic processing of C-terminally truncated NF-kappaB2 precursors at kappaB-containing promoters.

Guoliang Qing1, Zhaoxia Qu, Gutian Xiao.   

Abstract

The C-terminal, partially truncated forms of the NF-kappaB2/p52 precursor p100, p100DeltaCs, manifest constitutive processing and oncogenic ability, although the responsible mechanisms remain unknown. Here, we report that p100DeltaCs are specifically processed in association with binding to promoter DNA-containing kappaB sites. In the nucleus, p100DeltaCs bind to the kappaB promoter DNA and subsequently recruit the proteasome to form a stable proteasome/p100DeltaC/DNA complex, which mediates the processing of p100DeltaCs. Notably, the processing at the kappaB promoter is initiated by a proteasome-mediated endoproteolytic cleavage at amino acid D(415) of p100DeltaCs, and the processed p52, but not the precursors themselves, is oncogenic by up-regulating a subset of target genes. Our studies demonstrate a different mechanism of p100 processing and also present evidence showing that the proteasome modulates the action of transcription factors at promoter regions through endoproteolysis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363471      PMCID: PMC1838492          DOI: 10.1073/pnas.0609914104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Activation of IKKalpha and IKKbeta through their fusion with HTLV-I tax protein.

Authors:  G Xiao; S C Sun
Journal:  Oncogene       Date:  2000-10-26       Impact factor: 9.867

2.  Negative regulation of the nuclear factor kappa B-inducing kinase by a cis-acting domain.

Authors:  G Xiao; S C Sun
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

3.  Domain-specific interaction with the I kappa B kinase (IKK)regulatory subunit IKK gamma is an essential step in tax-mediated activation of IKK.

Authors:  G Xiao; E W Harhaj; S C Sun
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

4.  Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha.

Authors:  G Xiao; M E Cvijic; A Fong; E W Harhaj; M T Uhlik; M Waterfield; S C Sun
Journal:  EMBO J       Date:  2001-12-03       Impact factor: 11.598

5.  Regulation of NF-kappaB2/p100 processing by its nuclear shuttling.

Authors:  Gongxian Liao; Shao-Cong Sun
Journal:  Oncogene       Date:  2003-07-31       Impact factor: 9.867

6.  NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100.

Authors:  G Xiao; E W Harhaj; S C Sun
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

7.  Clinical significance of MHC class II-associated invariant chain expression in human gastric carcinoma.

Authors:  Yasuhiro Tamori; Xiaodong Tan; Kazuhiro Nakagawa; Eiji Takai; Junji Akagi; Toshiro Kageshita; Hiroshi Egami; Michio Ogawa
Journal:  Oncol Rep       Date:  2005-10       Impact factor: 3.906

Review 8.  Deregulation of NF-kappaB and its upstream kinases in cancer.

Authors:  Shao-Cong Sun; Gutian Xiao
Journal:  Cancer Metastasis Rev       Date:  2003-12       Impact factor: 9.264

9.  BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells.

Authors:  Estefania Claudio; Keith Brown; Sun Park; Hongshan Wang; Ulrich Siebenlist
Journal:  Nat Immunol       Date:  2002-09-23       Impact factor: 25.606

10.  Study of T-cell signaling by somatic cell mutagenesis and complementation cloning.

Authors:  Mary Ellen Cvijic; Gutian Xiao; Shao-Cong Sun
Journal:  J Immunol Methods       Date:  2003-07       Impact factor: 2.303

View more
  22 in total

1.  Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation.

Authors:  Jingjiao Zhou; Zhaoxia Qu; Fan Sun; Lei Han; Liwen Li; Shapei Yan; Laura P Stabile; Lin-Feng Chen; Jill M Siegfried; Gutian Xiao
Journal:  Cancer Immunol Res       Date:  2017-01-20       Impact factor: 11.151

Review 2.  The noncanonical NF-κB pathway.

Authors:  Shao-Cong Sun
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

3.  Oncovirus Kaposi sarcoma herpesvirus (KSHV) represses tumor suppressor PDLIM2 to persistently activate nuclear factor κB (NF-κB) and STAT3 transcription factors for tumorigenesis and tumor maintenance.

Authors:  Fan Sun; Yadong Xiao; Zhaoxia Qu
Journal:  J Biol Chem       Date:  2015-02-13       Impact factor: 5.157

4.  DNA methylation-dependent repression of PDZ-LIM domain-containing protein 2 in colon cancer and its role as a potential therapeutic target.

Authors:  Zhaoxia Qu; Pengrong Yan; Jing Fu; Jing Jiang; Michael J Grusby; Thomas E Smithgall; Gutian Xiao
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

Review 5.  Non-canonical NF-κB signaling pathway.

Authors:  Shao-Cong Sun
Journal:  Cell Res       Date:  2010-12-21       Impact factor: 25.617

6.  Epigenetic repression of PDZ-LIM domain-containing protein 2: implications for the biology and treatment of breast cancer.

Authors:  Zhaoxia Qu; Jing Fu; Pengrong Yan; Jing Hu; Shi-Yuan Cheng; Gutian Xiao
Journal:  J Biol Chem       Date:  2010-02-25       Impact factor: 5.157

7.  NF-κB and cancer: a paradigm of Yin-Yang.

Authors:  Gutian Xiao; Jing Fu
Journal:  Am J Cancer Res       Date:  2010-12-06       Impact factor: 6.166

8.  Molecular determinants of PDLIM2 in suppressing HTLV-I Tax-mediated tumorigenesis.

Authors:  J Fu; P Yan; S Li; Z Qu; G Xiao
Journal:  Oncogene       Date:  2010-09-13       Impact factor: 9.867

Review 9.  Strategies of oncogenic microbes to deal with WW domain-containing oxidoreductase.

Authors:  Yao Chang; Yu-Yan Lan; Jenn-Ren Hsiao; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2014-12-07

10.  Constitutive production of NF-kappaB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression.

Authors:  Zhe Wang; Baochun Zhang; Liqun Yang; Jane Ding; Han-Fei Ding
Journal:  J Biol Chem       Date:  2008-02-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.